trending Market Intelligence /marketintelligence/en/news-insights/trending/wlf0ad4af9s11aju3tuwlg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Savara prices common stock offering; proceeds to fund lung disease drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Savara prices common stock offering; proceeds to fund lung disease drug

Austin, Texas-based Savara Inc. priced its underwritten public offering of 4,250,000 common shares at $11.50 apiece.

The company has also granted the underwriters an option to buy up to an additional 637,500 shares.

Savara said the offering is expected to close July 30.

The company plans to use the net proceeds to fund clinical development and regulatory approvals and pre-commercialization activities for its product candidates, which include Molgradex, a lung disease drug.

Proceeds from the offering will be used to fund expansion of the Molgradex nontuberculous mycobacterial, or NTM, program with a new study in the U.S. in cystic fibrosis-affected individuals with chronic NTM lung infection.

In addition, the net proceeds are expected to be used for working capital and general corporate purposes, and general and administrative expenses.

Jefferies LLC and Evercore Group LLC are acting as joint book-running managers, with Canaccord Genuity LLC and JMP Securities LLC acting as lead managers for the offering. H.C. Wainwright & Co. LLC is acting as co-manager for the offering.

Savara is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases.